Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System

ABSTRACT Introduction Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shaimaa Elshafie, Lorenzo Villa‐Zapata, Randall L. Tackett, Iman Y. Zaghloul, Henry N. Young
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Cancer Medicine
Subjects:	adverse drug reactions breast cancer cardiovascular risk disproportionality analysis endocrine therapy FAERS database
Online Access:	https://doi.org/10.1002/cam4.70548
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
by: Hao Zhu, et al.
Published: (2025-03-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
by: He Chen, et al.
Published: (2025-05-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Zhiyuan Zhang, et al.
Published: (2024-11-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system
by: Dan Li, et al.
Published: (2025-05-01)

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
by: Bangbei Wan, et al.
Published: (2025-02-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
by: Jing Shi, et al.
Published: (2025-03-01)

Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system
by: Cheng Jiang, et al.
Published: (2025-07-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
by: Shanshan Xu, et al.
Published: (2025-07-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
by: Wensheng Liu, et al.
Published: (2025-05-01)

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system
by: Lingti Kong, et al.
Published: (2025-05-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
by: Chen Li, et al.
Published: (2025-05-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system
by: Guihao Zheng, et al.
Published: (2025-07-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)